

WEST Search History

DATE: Wednesday, January 10, 2007

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L1	Anti-cathepsin or antcathepsin	107
<input type="checkbox"/>	L2	Anti-cathepsin\$ or antcathepsin\$	110
<input type="checkbox"/>	L3	feces or fecal or stool or excrement or lavage	67099
<input type="checkbox"/>	L4	L3 and l2	7
	<i>DB=TDBD,DWPI,JPAB,EPAB,USOC,USPT,PGPB; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L5	(ANTI-CATHEPSIN ANTI-CATHEPSINS ANTI-CATHESPIN)!	102
<input type="checkbox"/>	L6	(ANTICATHEPSIN)!	14
<input type="checkbox"/>	L7	(ANCA)!	778
<input type="checkbox"/>	L8	(PANCA)!	121
<input type="checkbox"/>	L9	(P-ANCA P-ANCAS P-ANCA-CONTAINING P-ANCA-POSITIVE P-ANCA-SPECIFIC)!	56
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L10	(l5 or l6 or l7 or l8 or l9)	958
<input type="checkbox"/>	L11	L10 and l3 not l4	84
<input type="checkbox"/>	L12	(L10 same l3) not l4	16
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L13	mpo.clm. or lf.clm. or cat-g.clm. or (cat near g).clm.	390
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L14	mpo.clm. or lf.clm. or cat-g.clm. or (cat near g).clm.	785
<input type="checkbox"/>	L15	L14 and l3.clm.	1
<input type="checkbox"/>	L16	l3.clm. and lactoferrin.clm.	10

END OF SEARCH HISTORY

Digestive diseases and sciences.

Imprint: [New York, Plenum Pub. Corp.] 1979-

Notes: Available on ADONIS, v. 36, no. 1 (1991) - 47, no. 12 (2002)
Supplements accompany some issues.

ISSN: 0163-2116

Subjects: Nutrition -- Periodicals.
Digestive organs -- Diseases -- Periodicals.

Description: v. ill. 28 cm.

Continues: American journal of digestive diseases

[Add to my list](#)

WEST Search History

[Hide Items](#)
[Restore](#)
[Clear](#)
[Cancel](#)

DATE: Wednesday, January 10, 2007

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	Anti-cathepsin or antcathepsin	107
<input type="checkbox"/>	L2	Anti-cathepsin\$ or antcathepsin\$	110
<input type="checkbox"/>	L3	feces or fecal or stool or excrement or lavage	67099
<input type="checkbox"/>	L4	L3 and l2	7
		<i>DB=TDBD,DWPI,JPAB,EPAB,USOC,USPT,PGPB; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L5	(ANTI-CATHEPSIN ANTI-CATHEPSINS ANTI-CATHESPIN)!	102
<input type="checkbox"/>	L6	(ANTICATHEPSIN)!	14
<input type="checkbox"/>	L7	(ANCA)!	778
<input type="checkbox"/>	L8	(PANCA)!	121
<input type="checkbox"/>	L9	(P-ANCA P-ANCAS P-ANCA-CONTAINING P-ANCA-POSITIVE P-ANCA-SPECIFIC)!	56
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L10	(l5 or l6 or l7 or l8 or l9)	958
<input type="checkbox"/>	L11	L10 and l3 not l4	84
<input type="checkbox"/>	L12	(L10 same l3) not l4	16

END OF SEARCH HISTORY

Gastroenterology

April 1993 • Volume 104 • Number 4

Gut lavage fluid protein concentrations: Objective measures of disease activity in inflammatory bowel disease

C P Choudari [MEDLINE LOOKUP]
S O'Mahony [MEDLINE LOOKUP]
G Brydon [MEDLINE LOOKUP]
O Mwantembe [MEDLINE LOOKUP]
A Ferguson [MEDLINE LOOKUP]

- [Previous article](#) in Issue
- [Next article](#) in Issue
- [Drug links](#) from Mosby's DrugConsult
- [Genetic information](#) from OMIM
- Citation of this Article
 - [View on PubMed](#)
 - [Download in citation manager format](#)
 - [Download in Medlars format](#)
 - [Related articles](#) in PubMed

Abstract

TOP

BACKGROUND: Fluid obtained by whole gut lavage normally contains traces of immunoglobulin (Ig) G, albumin, and alpha-1-antitrypsin; higher concentrations have been found in patients with inflammatory bowel disease (IBD).

METHODS: In a prospective study, 53 lavages were performed in 45 IBD patients (27 Crohn's disease, 18 ulcerative colitis), in whom disease activity was simultaneously assessed by Crohn's Disease Activity Index or Powell Tuck index. Concentration of IgG in lavage fluid was measured by enzyme-linked immunosorbent assay, and of albumin and alpha-1-antitrypsin by immunoturbidimetry.

RESULTS: For IgG, concentrations in lavage fluid correlated closely with activity indices: in Crohn's disease, $r = 0.723$ ($P < 0.0001$), in ulcerative colitis, $r = 0.714$ ($P < 0.0001$). Results for albumin and alpha-1-antitrypsin concentrations were similar to those for IgG, but they were less sensitive in detecting active disease. However, this method cannot be used as a diagnostic test for IBD; normal results were obtained for IgG in 6 (all inactive) of 42 lavages in patients who had unequivocal radiological or endoscopic abnormalities.

CONCLUSIONS: Assay of protein concentrations in gut lavage fluid is a simple, objective means of grading disease activity in patients with IBD; its potential uses are likely to be in the evaluation of complex cases and in clinical trials.

(Gastroenterology 1993 Apr;104(4):1064-71)

Publishing and Reprint Information

TOP

- *Gastro-Intestinal Unit, Western General Hospital, Edinburgh, Scotland.*

Serologic Assays for Distinguishing Ulcerative Colitis and Crohn's Disease

Continued...

knowledge of the DNase sensitivity of P-ANCA detected in the IBD patient offers no advantage for classifying the IBD as UC or CD.

Based on data from animal studies, exposure to microbial antigens has been hypothesized to precipitate the development of CD. As indirect support for this hypothesis, sera from approximately 80% of CD patients contain IgG antibodies to a cell wall phosphopeptidomannan of *Saccharomyces cerevisiae* (hereafter abbreviated Sc). Approximately 50% of Sc IgG-positive CD patients are also Sc IgA-positive, and detection of both IgG and IgA to Sc is associated with fistulizing and fibrosing complications of CD. Approximately 20% of UC patients are also positive for Sc-IgG; however, Sc IgA is extremely rare in UC. In CD patients, Sc antibody levels usually normalize within a few years after surgical resection, suggesting that the Sc antibody response is triggered by uptake of the organism across the damaged mucosal barrier. Inconsistent with this view, however, is the lack of increased levels of antibodies to other yeasts found in the intestinal tract, such as *Candida*.

Benefits of Combination Testing

Although P-ANCA predominates in UC patients and Sc IgG predominates in CD, the overlapping subsets for each serologic marker leaves room for error when using the individual assays to classify IBD patients.

Recent studies have shown, however, that the predictive performance of these assays is enhanced if they are considered together. These findings were confirmed in validation studies performed at Focus Technologies using a panel of sera from clinically defined CD patients, clinically defined UC patients, and healthy controls. The findings of this in-house study are summarized in Table 1 on the previous page. Although Sc IgG detection had the highest sensitivity for CD, the P-ANCA-negative Sc IgG-positive reactivity pattern observed in combined testing had a higher specificity and PPV for CD than did Sc IgG detection alone (see results in bold under CD). Although Sc IgA detection (with or without Sc IgG) had the highest specificity and PPV for CD, its sensitivity was quite low. Similarly, P-ANCA detection was the most sensitive test for UC, but the P-ANCA-positive Sc IgG-negative reactivity pattern showed higher specificity and PPV for UC (see results in bold under UC). Thus, combined testing for P-ANCA and Sc antibodies is a useful tool that can be used in conjunction with clinical findings to distinguish CD and UC in an IBD patient group.

Lactoferrin Detection to Differentiate IBD and IBS

Focus also offers Stool Lactoferrin Detection, EIA, to differentiate true inflammatory bowel disease from active irritable bowel syndrome. The lactoferrin test is available as an individual assay or part of a panel.

REFERENCES

- ✓ Vasilias EA, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. *Gastroenterology* 110:1810-1819, 1996.
2. Brandtzaeg P, et al. Immunopathology of human inflammatory bowel disease. *Springer Semin Immunopathol* 18:555-589, 1997.
- ✓ 3. Abad E, et al. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. *J Autoimmunity* 10:175-180, 1997.
4. Barry MJ, et al. Advances in diagnostics for inflammatory bowel disease. *AMJ Interactions* 3:4-6, 1998.
- ✓ 5. Quinton J-F, et al. Anti-*Saccharomyces cerevisiae* mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. *Gut* 42:788-791, 1998.
- ✓ 6. Ruemmele FM, et al. Diagnostic accuracy of serologic assays in pediatric inflammatory bowel disease. *Gastroenterology* 115:822-829, 1998.
- ✓ 7. Hoffenberg EJ, et al. Serologic testing for inflammatory bowel disease. *J Pediatr* 134:447-452, 1999.
8. Roozendaal C, et al. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? *Immunology* 116:206-213, 1999.

Code # Test Description

5800 Inflammatory Bowel Disease Assessment Panel

Panel Includes: Lactoferrin Detection EIA (Stool); *S. Cerevisiae* Antibody Panel, ELISA; and Anti-Neutrophil Cytoplasmic Antibody (ANCA)
Preferred Specimen: 2 mL serum (minimum 1 mL) Transport Temperature: 2-8° C CPT Code: 86671 x 2; 86255; 83516
1 gram fresh or preserved stool or FROZEN
≤48 hours post collection if >48 hours

5515 Inflammatory Bowel Disease Differentiation Panel

Panel Includes: *S. Cerevisiae* Antibody Panel, ELISA; and Anti-Neutrophil Cytoplasmic Antibody (ANCA)
Preferred Specimen: 2 mL serum (minimum 1 mL) Transport Temperature: 2-8° C CPT Code: 86671 x 2; 86255

52800 Lactoferrin Detection, EIA (Stool)

Preferred Specimen: 1 gram fresh or preserved stool Transport Temperature: 2-8° C CPT Code: 83516
≤48 hours post collection or FROZEN if >48 hours

40237 *Saccharomyces cerevisiae* Antibody Panel, ELISA

Preferred Specimen: 1 mL serum (minimum 0.5 mL) Transport Temperature: 2-8° C CPT Code: 86671 x 2

Focus Technologies offers a comprehensive menu of tests for gastrointestinal infections and autoimmune diseases.

To send specimens or obtain additional information, please contact our Client Services Department at
800 445 4032.

For technical assistance, contact Focus Technologies' Technical Director of Immunology.

FOCUS
technologies

800 445 0185 714 220 1900 Fax: 714 220 9213
Cypress, California 90630 USA
www.focustechnologies.com

RLT8D0204

#18 Search stool autoantibodies Field: Title	14:21:21	
#17 Search stool autoimmune Field: Title	14:21:16	
#16 Search fecal autoimmune Field: Title	14:21:10	
#15 Search fecal autoantibody Field: Title	14:21:05	
#14 Search fecal autoantibodies Field: Title	14:20:57	
#13 Search feces autoantibodies Field: Title	14:20:51	
#12 Search feces crohn's Field: Title	14:20:18	
#11 Search feces ibd Field: Title	14:20:05	
#10 Search measurement feces Field: Title	14:19:15	
#8 Search #7 and anti-saccharomyces	14:17:48	
#7 Search feces or fecal or stool Field: Title	14:17:20	<u>101</u>
#4 Search anti-saccharomyces feces	14:15:12	
#3 Search anti-saccharomyces	14:15:05	<u>1</u>
#1 Search raised stool serum iga levels		